Effect of aspirin use on survival in patients with hepatocellular carcinoma

Hepatocellular carcinoma (HCC) is the seventh most prevalent cancer globally and is the third leading cause of cancer-related mortality.

The aim of this study was to evaluate the effect of aspirin use on the survival rates of individuals diagnosed with HCC.

The patients were divided into two groups: those who used aspirin and those who did not. Aspirin use was defined as individuals who had used aspirin either before or after the diagnosis of HCC. Aspirin usage was determined based on prescription records. The criteria for aspirin use were defined as a minimum of 3 months and a minimum daily dose of 100 mg. Survival time; The time elapsed after the diagnosis of HCC was calculated as 'months'.

Of the 300 cohorts studied in our study, 104 (34.6%) were using aspirin, while 196 (65.4%) were not. It was observed that bleeding occurred only in the patient group taking aspirin ( P  = 0.002). When evaluated in terms of survival time, it was observed that it was significantly higher in the patient group using aspirin ( P  = 0.001). Aspirin use was identified as factors that significantly impact survival ( P  < 0.05). Aspirin use was identified as independent risk factors that significantly impact of survival ( P  < 0.05).

The aspirin group had a similar metabolic and liver reserve as the other group and had a longer survival despite being older and more comorbid diseases.